Podcast: Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets
Tracking # 20-1338008
What you'll learn
At the conclusion of this course, participants will be able to:
- Differentiate the clinical and pathological characteristics between neuroendocrine tumors (NETs) and NECs
- Apply key diagnostic criteria for evaluating EP-NEC to minimize misdiagnosis and diagnostic delays and facilitate timely initiation of appropriate treatment
- Outline evidence-based treatment strategies for patients with EP-NEC, including first-line therapies and approaches for progressive or relapsed disease
- Evaluate the role of DLL3 as an emerging therapeutic target in EP-NEC, including the rationale for its use and supporting evidence
Course overview
Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Medical Practitioner
Specialty Medical Practitioner
Florida Board of Medicine
Anesthesiologist Assistant
Area of Critical Need Medical Doctor
Medical Doctor
Medical Doctor Faculty Certificate
Medical Doctor Limited License
Medical Doctor Limited to Cleveland Clinic
Medical Doctor Limited to Mayo Clinic
Medical Doctor Public Health Certificate
Medical Doctor Public Psychiatry
Medical Doctor Visiting Faculty Certificate
Florida Board of Pharmacy
Pharmacist
Registered Pharmacy Technician
Florida Physician Assistants
Physician Assistant
Physician Assistant Temporary Certificate for Practice in Areas of Critical Need
Georgia Composite Medical Board - Physician Assistants
Physician Assistant
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
Physician and Surgeon Compact License
Michigan Board of Medicine
Medical Doctor
Medical Doctor Compact License
Michigan Board of Pharmacy
Pharmacist
Pharmacist Special Volunteer
Pharmacy Technician
Pharmacy Technician Special Volunteer
Mississippi State Board of Medical Licensure
Doctor of Osteopathy
Medical Doctor
Physician Assistant
New Hampshire Board of Medicine
Physician
New Hampshire Board of Pharmacy
Pharmacist
Oklahoma Board of Medical Licensure and Supervision - Medical Doctors
Medical Doctor
Oklahoma Board of Medical Licensure and Supervision - Physician Assistants
Physician Assistant
South Carolina Board of Medical Examiners
Doctor of Osteopathy
Medical Doctor
Tennessee Board of Medical Examiners
Medical Doctor
Texas Medical Board - Physicians
Physician
Wisconsin Medical Examining Board
Physician
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer.
Danielle Hutchings, MD, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 0.75 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-031-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
Take it Here
- This course reports to CE Broker immediately upon completion.
- Complete all courses at your own pace online.
- Quality and enjoyable courses.
- Modern experience, accessible from any device.
- All courses affordably priced.